Last reviewed · How we verify

Continuation of insulin glargine

Providence Health & Services · FDA-approved active Small molecule

Insulin glargine is a long-acting basal insulin that binds to insulin receptors to lower blood glucose by promoting glucose uptake into cells and inhibiting hepatic glucose production.

Insulin glargine is a long-acting basal insulin that binds to insulin receptors to lower blood glucose by promoting glucose uptake into cells and inhibiting hepatic glucose production. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

At a glance

Generic nameContinuation of insulin glargine
Also known asLantus
SponsorProvidence Health & Services
Drug classLong-acting basal insulin
TargetInsulin receptor
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

Insulin glargine is a recombinant human insulin analog modified to have an extended duration of action (approximately 24 hours). It binds to the insulin receptor on target tissues, facilitating glucose transport into muscle and adipose tissue while suppressing gluconeogenesis and glycogenolysis in the liver. This provides steady basal insulin coverage for glycemic control in diabetes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: